Lonza reports 12% sales growth in 2020
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
Subscribe To Our Newsletter & Stay Updated